Pharmacogenomics Presentation Assignment
CYP 2C9*2 and CYP 2C9*3
How does this genetic variant affect the efficacy and/or toxicity of a drug or drugs?
Do you see such an effect in specific patient populations?
Describe the clinical relevance of the genetic variant and affected drug therapy.
When considering drug therapy with the affected drug(s), is genetic testing for this association available, required, or covered by payors?
What else did you learn about this genetic variant that you found interesting?
===>
CYP 2C92 and CYP 2C93 are genetic variants of the cytochrome P450 2C9 enzyme that can affect the metabolism of certain drugs. These variants can lead to decreased enzyme activity, resulting in higher blood levels of the drugs metabolized by this enzyme, such as warfarin, phenytoin, and non-steroidal anti-inflammatory drugs (NSAIDs). This can increase the risk of toxicity or reduce the efficacy of the drugs.
These genetic variants are particularly prevalent in certain patient populations, such as African Americans and Asians, who have a higher frequency of the CYP 2C9*3 allele.
The clinical relevance of these variants is that they can affect the response to certain drugs, and therefore, it is important to consider a patient’s genetic profile when prescribing these drugs. Genetic testing for these variants can be used to guide drug therapy, for example warfarin dosing.
Genetic testing for this association is available and is sometimes required or covered by payors, but it depends on the specific payor and the specific drug being prescribed.
It is interesting to note that, in addition to its role in drug metabolism, CYP 2C9 also plays a role in the metabolism of certain endocannabinoids, which are compounds produced by the body that are similar in structure to the active ingredient in cannabis. This suggests that genetic variants of this enzyme may also affect the response to cannabis-based therapy.
